Kinase Inhibitors

Kinase Inhibitor

P-Glycoprotein Inhibitors

Organic Cation Transporter 2 Inhibitors

Multidrug and Toxin Extrusion Transporter 1 Inhibitors

Cholangiocarcinoma

<section class="Section" data-sectioncode="34089-3"><a name="LINK_5fa43624-d552-46ab-9679-0f37ec0aad5c"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Pemigatinib is a kinase inhibitor with the chemical name 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2<span class="Italics">H</span>-pyrrolo[3',2':5,6]pyrido[4,3-<span class="Italics">d</span>]pyrimidin-2-one. Pemigatinib has a molecular formula of C<span class="Sub">24</span>H<span class="Sub">27</span>F<span class="Sub">2</span>N<span class="Sub">5</span>O<span class="Sub">4</span> and molecular mass of 487.5 g/mole. Pemigatinib has the following chemical structure:</p><div class="Figure"><img alt="Chemical Structure" src="pemazyre-1.jpg"/></div><p>Pemigatinib is a white to off-white solid that is not hygroscopic. The solubility of pemigatinib is pH dependent with decreasing solubility observed with increasing pH. PEMAZYRE tablets are uncoated and for oral administration. Tablets are available containing 4.5 mg, 9 mg, or 13.5 mg of pemigatinib active ingredient. The inactive ingredients include magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.</p></section>

PEMAZYRE

pemigatinib

pemigatinib 13.5 MG Oral Tablet

Pemazyre

pemigatinib 13.5 MG Oral Tablet [Pemazyre]

pemigatinib 4.5 MG Oral Tablet

pemigatinib 4.5 MG Oral Tablet [Pemazyre]

pemigatinib 9 MG Oral Tablet

pemigatinib 9 MG Oral Tablet [Pemazyre]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

How To Order Pemazyre

Billing & Coding Guide 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity

IncyteCARES for Pemazyre Enrollment Form

IncyteCARES for Pemazyre Enrollment Form - Online 

Enroll in Patient Savings Program - HCP Office 

Enroll in Patient Savings Program - Patient

IncyteCARES for Pemazyre Patient Assistance Program

IncyteCARES for Pemazyre Temporary Access Program

Other HCP Resources: Metastatic Cholangiocarcinoma with FGFR2 Fusion

Instructions For Use: Metastatic Cholangiocarcinoma with FGFR2 Fusion

About Pemazyre: Metastatic Cholangiocarcinoma with FGFR2 Fusion

Taking Pemazyre: Metastatic Cholangiocarcinoma with FGFR2 Fusion

IncyteCARES for Pemazyre Patient Support Program: Metastatic Cholangiocarcinoma with FGFR2 Fusion

Side Effect Discussion Guide: Metastatic Cholangiocarcinoma with FGFR2 Fusion

Patient Resources: Metastatic Cholangiocarcinoma with FGFR2 Fusion

Treatment Tracker

Instructions For Use: Myeloid/Lymphoid Neoplasms